254 Results
announced positive coverage decisions from four private payers including Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Health Plan (CDPHP) of New York
Biodesix announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company’s Board of Directors effective January 3, 2023.
Biodesix today announced that new data were published in the peer-reviewed journal, Diagnostics (Basel), in an article titled, “Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants.”
Biodesix will release financial results for the third quarter before the open of trading on November 3. Biodesix’s will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. ET.
Biodesix announced today that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.
First Quarter 2022 Financial Results
Biodesix named the leading Proteomics Solutions Company in the U.S. by Life Sciences Review Magazine issue, Top 10 Proteomics Solutions Companies of 2022.
Biodesix CEO named in The Healthcare Technology Report’s list of Top 25 Biotech CEOs of 2022, recognizing the most accomplished executives in biotech.
Genomic and proteomic diagnostics for lung cancer help physicians better identify patients eligible for targeted therapy or clinical trial enrollment.
Biodesix announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions.
Biodesix announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses.
Biodesix announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare.
Data confirms the ability of the VeriStrat® test to predict outcomes in patients with Non-small Cell Lung Cancer treated with immunotherapy regimens.
Third quarter 2022 core Lung Diagnostic revenue of $9.2 million increased 102% over the comparable period in 2021; U.S. Federal Supply Schedule Contract expands coverage to Veterans Health Administration and Military Health System Medical Centers for its entire Lung Diagnostic portfolio.
Biodesix Expands Coverage to Veterans Health Administration and Military Health System Medical Centers for Its Entire Lung Diagnostic Portfolio
Biodesix expects to report third quarter 2022 total revenue to be in the range of $10.6 million to $11.2 million, representing growth of 62% to 71% over the third quarter 202, reflecting continued growth in the Company’s core lung diagnostic testing.
Biodesix to participate at Morgan Stanley 20th Annual Global Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference
Biodesix, Inc. (Nasdaq: BDSX) announced its financial and operating results for second quarter ended June 30, 2022 and provided a corporate update.
Rewatch the live fireside chat during Canaccord Genuity 42nd Annual Growth Conference, featuring Scott Hutton, CEO of Biodesix Inc.
Biodesix is recognized in the Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022.
Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods
Adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment
The Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, provides coverage for the Nodify CDT® lung nodule test.
Aim is to develop and commercialize new pipeline oncology biomarker assay in collaboration with Memorial Sloan Kettering Cancer Center and Bio-Rad, Inc.
Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9 in Chicago
Biodesix announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting.
